AbbVie agreed to acquire Capstan Therapeutics for up to $2.1B in cash. Gains CPTX2309 (Phase 1 in vivo anti-CD19 CAR-T for B-cell autoimmune diseases) and Capstan's proprietary tLNP platform for RNA delivery enabling in vivo cell engineering. Completed August 19, 2025.